Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | ATP4A | P20648 | 1/20 | 0.41 |
| ▸ | ATP4B | P51164 | 1/20 | 0.41 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.41 |
| ▸ | MGMT | P16455 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CDK1 | P06493 | 2/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1775713 | 0.87 | L3MBTL1 (0.51) | L3MBTL1LTA4HMAPK14EGLN1CYP3A4 | |
| SCHEMBL2400897 | 0.83 | L3MBTL1 (0.53) | L3MBTL1CYP3A4PDE5AMGMTKDM4E | |
| SCHEMBL312573 | 0.79 | MGMT (0.53) | L3MBTL1EGLN1MGMTLMNAPIN1 | |
| SCHEMBL311056 | 0.76 | MGMT (0.59) | L3MBTL1LTA4HMAPK14MGMTLMNA | |
| SCHEMBL1232862 | 0.75 | L3MBTL1 (0.57) | L3MBTL1LTA4HMAPK14CYP3A4PDE5A | |
| SCHEMBL2399974 | 0.72 | KDM4E (0.49) | L3MBTL1LTA4HMAPK14EGLN1CYP3A4 | |
| SCHEMBL312251 | 0.72 | CYP3A4 (0.49) | L3MBTL1LTA4HMAPK14CYP3A4PDE5A | |
| SCHEMBL2400247 | 0.72 | L3MBTL1 (0.47) | L3MBTL1LTA4HMAPK14EGLN1CYP3A4 | |
| SCHEMBL13313402 | 0.71 | L3MBTL1 (0.49) | L3MBTL1LTA4HMAPK14CYP3A4PDE5A | |
| SCHEMBL16852229 | 0.71 | MGMT (0.64) | L3MBTL1LTA4HMAPK14CYP3A4PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8378102-B2 | Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-02-19 | — | — | US | disclosed |
| US-8026366-B2 | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-09-27 | — | — | US | disclosed |
| US-20100240693-A1 | Oxime and Hydroxylamine Substituted Thiazolo [4,5-C] Ring Compounds and Methods | COLEY PHARMACEUTICAL GROUP, INC (US) | 2010-09-23 | — | — | US | disclosed |
| EP-1877056-A2 | OXIME AND HYDROXYLAMINE SUBSTITUTED THIAZOLOÝ4,5-C¨RING COMPOUNDS AND METHODS | Coley Pharmaceutical Group, Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| WO-2007120121-A2 | OXIME AND HYDROXYLAMINE SUBSTITUTED THIAZOLO[4,5-C] RING COMPOUNDS AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070208052-A1 | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-09-06 | — | — | US | disclosed |
| WO-2006009826-A1 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208052-A1 | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines | IL2, TSLP, IFNG | L3MBTL1 2999/4885LTA4H 448/4885MAPK14 1120/4885 |
| US-20100240693-A1 | Oxime and Hydroxylamine Substituted Thiazolo [4,5-C] Ring Compounds and Methods | IL4, IL2, TH | L3MBTL1 3690/4885LTA4H 626/4885MAPK14 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.